Developer docs
API playgroundTry for free, no card

Search company profiles

APR Applied Pharma Research

Full company profile

uuid0009y9f

Namestring
APR Applied Pharma Research
Legal namestring
APR Applied Pharma Research s.a.
Websiteurl
apr.ch
Company typeenum
Private
Founded yearint
1990
Descriptiontext

APR Applied Pharma Research s.a. is a Swiss pharmaceutical company headquartered in Balerna, Ticino, Switzerland, and a wholly owned subsidiary of Relief Therapeutics Holding AG (SIX: RLF.SW). Founded in 1990, the company identifies, develops, and commercializes patent-protected prescription and consumer healthcare products in niche and rare therapeutic areas, with a stated focus on inherited metabolic disorders (Phenylketonuria), advanced wound care, cancer supportive care, acute pain/migraine, and rare dermatological and ocular diseases.

The product portfolio is built on four proprietary technology platforms. Physiomimic Technology underpins the PKU GOLIKE family (Plus, KRUNCH, BAR) of phenylalanine-free amino acid formulations for PKU dietary management, using a coated-granule architecture that delivers gradual, prolonged release over up to 7 hours and masks taste/odor. Tehclo Technology is a patented hypochlorous-acid nanotechnology platform used in Nexodyn AcidOxidizing Solution (a Class III EU medical device) for chronic wound care, and is also being applied to pipeline assets for Epidermolysis Bullosa (APR TD011), Hailey-Hailey Disease (APR TD012), and ocular surface diseases (APR 1204). Dynamic Buffering Technology enables an immediate-release Diclofenac K formulation with faster onset; Oral Dispersible Film (ODF) technology powers Setofilm (Ondansetron) for cancer supportive care. Consumer brands include Halykoo (pediatric OTC) and SwitzAGE (healthy aging nutraceuticals).

APR operates a dual business model. First, it generates product revenue through a mix of direct sales teams in Italy, Germany, Switzerland, and Austria, combined with an extensive network of commercial partners reaching over 70 countries (with named third-party distributors for Spain and the UK). Second, it provides contract development services to third-party pharmaceutical companies on a fee-for-service basis across solid, non-solid, and analytical services. Revenue and pricing details are not publicly disclosed; the company is GMP-, GDP-, and ISO 13485-certified (Swissmedic / TÜV SÜD) and holds authorization for handling controlled substances.

Short descriptiontext

APR Applied Pharma Research is a Swiss pharmaceutical company (wholly owned by Relief Therapeutics) that develops and commercializes patent-protected branded products in niche and rare disease areas, including PKU dietary management, advanced wound care, cancer supportive care, and rare dermatological/ocular conditions, selling through direct European sales and a partner network spanning 70+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBalerna, Switzerland
HQ citystring
Balerna
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, drug delivery technologies, rare disease therapeutics, medical foods, contract pharmaceutical development
Industry2 codes
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
  • Scientific Research and Development Services5417
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

APR generates revenue from a balanced portfolio of revenue-generating branded products marketed in all major markets, including prescription healthcare products (PKU GOLIKE, Nexodyn, Diclofenac, Setofilm) and consumer healthcare OTC products (Halykoo, SwitzAGE).

apr.ch
2Contract R&D Services
TypeProfessional Services
Description

Provides added-value R&D services under contract and on a fee-for-service basis including research and development services, complete project supervision, management and execution, development of oral and topical formulations and customized drug delivery technologies.

apr.ch
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1PKU GOLIKE
Description

Innovative food for special medical purposes (FSMP) consisting of Phe-free amino acid mixture for Phenylketonuria dietary management, powered by Physiomimic Technology

apr.ch
+4 more records
Core offering1 text field

APR Applied Pharma Research is a Swiss pharmaceutical company that identifies, develops, and commercializes patent-protected, science-driven products in niche and rare therapeutic areas. It markets branded prescription healthcare products (PKU GOLIKE family, Nexodyn, Diclofenac IR, Setofilm) and consumer healthcare OTC products (Halykoo, SwitzAGE), and additionally provides contract R&D and formulation development services on a fee-for-service basis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Prolonged amino acid release up to 7 hours
+4 more records
Product overview1 text field

APR Applied Pharma Research is a Swiss pharmaceutical company that identifies, develops, and commercializes best-in-class, patent-protected products in selected rare and ultra-rare disease areas. The company's product portfolio is built on proprietary technology platforms and includes prescription healthcare products and consumer healthcare products. The main marketed products include: PKU GOLIKE family (Plus, KRUNCH, and BAR) - food for special medical purposes for Phenylketonuria dietary management powered by Physiomimic Technology; Nexodyn AcidOxidizing Solution - advanced wound cleanser powered by Tehclo Technology; Diclofenac Immediate Release - for migraine and acute pain using Dynamic Buffering Technology; Setofilm - oral film Ondansetron for cancer supportive care using ODF technology; and consumer products including Halykoo pediatric range and SwitzAGE nutraceuticals. APR also provides contract development and manufacturing services (CDMO) to the pharmaceutical industry.

Product and service1 record
1PKU GOLIKE Plus
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1APR Applied Pharma Research - Italy S.r.l.
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

EU representative and exclusive distributor of PKU GOLIKE products for Italy. Located in Rome with operations in Monza.

apr.ch
2APR Applied Pharma Research - Deutschland GmbH
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for PKU GOLIKE products in Germany, Austria, and Switzerland. Located in Offenbach, Germany.

apr.ch
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for PKU GOLIKE products in Spain. Located in Madrid, Spain.

4Meta Healthcare LTD
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Distributor for PKU GOLIKE products in the UK. Located in Hemel Hempstead, United Kingdom.

apr.ch
5Global Pharmaceutical Partners
Strategic tierMajorTypeChannel Partner/ Reseller/ Distributor
Description

Extensive network of partnerships with pharmaceutical companies internationally sized for distribution in over 70 countries worldwide.

apr.ch
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty/rare-disease biotech with the most relevant overlap in PKU therapeutics (Kuvan, Palynziq). Operates in the same niche rare metabolic indication with proprietary formulation approaches, making it the closest functional peer to APR's PKU GOLIKE franchise.

TypeDirect peer
Description

Global medical products company with a sizable Advanced Wound Care business (AQUACEL, InnovaMatrix). Competes head-to-head with Nexodyn AOS in advanced wound management and shares focus on chronic, hard-to-heal wounds.

TypeDirect peer
Description

European specialty pharma with an explicit Rare Diseases business unit covering metabolic, endocrine, and ultra-rare indications. Closely comparable in therapeutic-area focus, European commercial model, and emphasis on patented niche products.

TypeBroad incumbent
Description

European specialty pharma with a dermatology-led portfolio including rare/skin disease treatments. Comparable to APR in targeting niche dermatology (Epidermolysis Bullosa, Hailey-Hailey) with proprietary formulations, though Almirall is significantly larger and broader.

TypeBroad incumbent
Description

Privately held European pharma with established rare disease franchises (e.g., haemophilia, lysosomal storage disorders). Overlaps in rare disease specialty therapeutics and proprietary respiratory/specialty delivery platforms, though much broader in portfolio scale than APR.

TypeBroad incumbent
Description

Large diversified wound care franchise with advanced and surgical wound management products serving hospitals and home care. Overlaps with APR's Nexodyn chronic wound strategy at a much broader global scale.

TypeDirect peer
Description

Through its Vitaflo and broader medical nutrition portfolio, Nestlé Health Science is a leading provider of PKU medical foods and low-protein nutritional products. Directly competes with the PKU GOLIKE range in diet management of phenylketonuria.

TypeDirect peer
Description

Nutricia's Metabolic and Rare Disease unit supplies amino acid-based medical foods for PKU and related inherited metabolic disorders across Europe. Direct overlap with APR's PKU GOLIKE Plus, KRUNCH and BAR formulations in phenylketonuria dietary management.

TypeDirect peer
Description

Specialty biotech dedicated to rare diseases (haematology, immunology, specialty care) with European commercial footprint. Comparable as a focused rare-disease commercializer operating globally in specialty/rare indications.

10Ajinomoto Health & Nutrition (formerly Cambrooke Therapeutics)
TypeDirect peer
Description

Acquired Cambrooke Therapeutics, a focused PKU and rare metabolic disorder medical food company providing amino acid formulas comparable to PKU GOLIKE. Direct competitor in the inherited metabolic disease dietary management category.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

APR Applied Pharma Research

Specialty Pharmaceuticalsapr.ch

APR Applied Pharma Research is a Swiss pharmaceutical company (wholly owned by Relief Therapeutics) that develops and commercializes patent-protected branded products in niche and rare disease areas, including PKU dietary management, advanced wound care, cancer supportive care, and rare dermatological/ocular conditions, selling through direct European sales and a partner network spanning 70+ countries.

What APR Applied Pharma Research does

APR Applied Pharma Research s.a. is a Swiss pharmaceutical company headquartered in Balerna, Ticino, Switzerland, and a wholly owned subsidiary of Relief Therapeutics Holding AG (SIX: RLF.SW). Founded in 1990, the company identifies, develops, and commercializes patent-protected prescription and consumer healthcare products in niche and rare therapeutic areas, with a stated focus on inherited metabolic disorders (Phenylketonuria), advanced wound care, cancer supportive care, acute pain/migraine, and rare dermatological and ocular diseases.

The product portfolio is built on four proprietary technology platforms. Physiomimic Technology underpins the PKU GOLIKE family (Plus, KRUNCH, BAR) of phenylalanine-free amino acid formulations for PKU dietary management, using a coated-granule architecture that delivers gradual, prolonged release over up to 7 hours and masks taste/odor. Tehclo Technology is a patented hypochlorous-acid nanotechnology platform used in Nexodyn AcidOxidizing Solution (a Class III EU medical device) for chronic wound care, and is also being applied to pipeline assets for Epidermolysis Bullosa (APR TD011), Hailey-Hailey Disease (APR TD012), and ocular surface diseases (APR 1204). Dynamic Buffering Technology enables an immediate-release Diclofenac K formulation with faster onset; Oral Dispersible Film (ODF) technology powers Setofilm (Ondansetron) for cancer supportive care. Consumer brands include Halykoo (pediatric OTC) and SwitzAGE (healthy aging nutraceuticals).

APR operates a dual business model. First, it generates product revenue through a mix of direct sales teams in Italy, Germany, Switzerland, and Austria, combined with an extensive network of commercial partners reaching over 70 countries (with named third-party distributors for Spain and the UK). Second, it provides contract development services to third-party pharmaceutical companies on a fee-for-service basis across solid, non-solid, and analytical services. Revenue and pricing details are not publicly disclosed; the company is GMP-, GDP-, and ISO 13485-certified (Swissmedic / TÜV SÜD) and holds authorization for handling controlled substances.

APR Applied Pharma Research firmographics

Firmographics
Name
APR Applied Pharma Research
Legal name
APR Applied Pharma Research s.a.
Website
https://apr.ch
Company type
Private
Founded year
1990
Operating status
Operating
Headcount range
11–50 employees
Short description
APR Applied Pharma Research is a Swiss pharmaceutical company (wholly owned by Relief Therapeutics) that develops and commercializes patent-protected branded products in niche and rare disease areas, including PKU dietary management, advanced wound care, cancer supportive care, and rare dermatological/ocular conditions, selling through direct European sales and a partner network spanning 70+ countries.
Ownership category
akta.pro rank

APR Applied Pharma Research industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Drug delivery technologies
  • Rare disease therapeutics
  • Medical foods
  • Contract pharmaceutical development

Where APR Applied Pharma Research is headquartered

Location

Headquarters

HQ city
Balerna
HQ country
Switzerland
HQ region
Europe

Offices6 records

Markets served

APR Applied Pharma Research business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: APR generates revenue from a balanced portfolio of revenue-generating branded products marketed in all major markets, including prescription healthcare products (PKU GOLIKE, Nexodyn, Diclofenac, Setofilm) and consumer healthcare OTC products (Halykoo, SwitzAGE).
  2. Contract R&D Services: Provides added-value R&D services under contract and on a fee-for-service basis including research and development services, complete project supervision, management and execution, development of oral and topical formulations and customized drug delivery technologies.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels3 records

APR Applied Pharma Research product offering

Product offering

Core offering

APR Applied Pharma Research is a Swiss pharmaceutical company that identifies, develops, and commercializes patent-protected, science-driven products in niche and rare therapeutic areas. It markets branded prescription healthcare products (PKU GOLIKE family, Nexodyn, Diclofenac IR, Setofilm) and consumer healthcare OTC products (Halykoo, SwitzAGE), and additionally provides contract R&D and formulation development services on a fee-for-service basis.

Product overview

APR Applied Pharma Research is a Swiss pharmaceutical company that identifies, develops, and commercializes best-in-class, patent-protected products in selected rare and ultra-rare disease areas. The company's product portfolio is built on proprietary technology platforms and includes prescription healthcare products and consumer healthcare products. The main marketed products include: PKU GOLIKE family (Plus, KRUNCH, and BAR) - food for special medical purposes for Phenylketonuria dietary management powered by Physiomimic Technology; Nexodyn AcidOxidizing Solution - advanced wound cleanser powered by Tehclo Technology; Diclofenac Immediate Release - for migraine and acute pain using Dynamic Buffering Technology; Setofilm - oral film Ondansetron for cancer supportive care using ODF technology; and consumer products including Halykoo pediatric range and SwitzAGE nutraceuticals. APR also provides contract development and manufacturing services (CDMO) to the pharmaceutical industry.

Differentiator

Problem solved

Functional benefit

Brands

  • PKU GOLIKE: Innovative food for special medical purposes (FSMP) consisting of Phe-free amino acid mixture for Phenylketonuria dietary management, powered by Physiomimic Technology
  • Nexodyn
  • Setofilm
  • Halykoo
  • SwitzAGE

Products and services

  • PKU GOLIKE Plus

Quantifiable outcome

  • Prolonged amino acid release up to 7 hours
  • +4 more outcomes

Companies that use APR Applied Pharma Research

Customer profile

Segments6 records

Ideal customer profiles4 records

APR Applied Pharma Research technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

APR Applied Pharma Research partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • APR Applied Pharma Research - Italy S.r.l.coreChannel Partner/ Reseller/ DistributorEU representative and exclusive distributor of PKU GOLIKE products for Italy. Located in Rome with operations in Monza.
  • APR Applied Pharma Research - Deutschland GmbHcoreChannel Partner/ Reseller/ DistributorDistributor for PKU GOLIKE products in Germany, Austria, and Switzerland. Located in Offenbach, Germany.
  • Rendon Europe Laboratories S.L.majorChannel Partner/ Reseller/ DistributorDistributor for PKU GOLIKE products in Spain. Located in Madrid, Spain.
  • Meta Healthcare LTDmajorChannel Partner/ Reseller/ DistributorDistributor for PKU GOLIKE products in the UK. Located in Hemel Hempstead, United Kingdom.
  • Global Pharmaceutical PartnersmajorChannel Partner/ Reseller/ DistributorExtensive network of partnerships with pharmaceutical companies internationally sized for distribution in over 70 countries worldwide.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

APR Applied Pharma Research competitors and assessment

Company assessment

Direct peers

  • BioMarin Pharmaceutical: Specialty/rare-disease biotech with the most relevant overlap in PKU therapeutics (Kuvan, Palynziq). Operates in the same niche rare metabolic indication with proprietary formulation approaches, making it the closest functional peer to APR's PKU GOLIKE franchise.
  • ConvaTec: Global medical products company with a sizable Advanced Wound Care business (AQUACEL, InnovaMatrix). Competes head-to-head with Nexodyn AOS in advanced wound management and shares focus on chronic, hard-to-heal wounds.
  • Recordati Rare Diseases: European specialty pharma with an explicit Rare Diseases business unit covering metabolic, endocrine, and ultra-rare indications. Closely comparable in therapeutic-area focus, European commercial model, and emphasis on patented niche products.
  • Nestlé Health Science: Through its Vitaflo and broader medical nutrition portfolio, Nestlé Health Science is a leading provider of PKU medical foods and low-protein nutritional products. Directly competes with the PKU GOLIKE range in diet management of phenylketonuria.
  • Nutricia (Danone): Nutricia's Metabolic and Rare Disease unit supplies amino acid-based medical foods for PKU and related inherited metabolic disorders across Europe. Direct overlap with APR's PKU GOLIKE Plus, KRUNCH and BAR formulations in phenylketonuria dietary management.
  • Sobi (Swedish Orphan Biovitrum): Specialty biotech dedicated to rare diseases (haematology, immunology, specialty care) with European commercial footprint. Comparable as a focused rare-disease commercializer operating globally in specialty/rare indications.
  • Ajinomoto Health & Nutrition (formerly Cambrooke Therapeutics): Acquired Cambrooke Therapeutics, a focused PKU and rare metabolic disorder medical food company providing amino acid formulas comparable to PKU GOLIKE. Direct competitor in the inherited metabolic disease dietary management category.

Broad incumbents

  • Almirall: European specialty pharma with a dermatology-led portfolio including rare/skin disease treatments. Comparable to APR in targeting niche dermatology (Epidermolysis Bullosa, Hailey-Hailey) with proprietary formulations, though Almirall is significantly larger and broader.
  • Chiesi Farmaceutici: Privately held European pharma with established rare disease franchises (e.g., haemophilia, lysosomal storage disorders). Overlaps in rare disease specialty therapeutics and proprietary respiratory/specialty delivery platforms, though much broader in portfolio scale than APR.
  • Smith & Nephew: Large diversified wound care franchise with advanced and surgical wound management products serving hospitals and home care. Overlaps with APR's Nexodyn chronic wound strategy at a much broader global scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

APR Applied Pharma Research social profiles

Digital presence

APR Applied Pharma Research compliance and trust

Trust signal

Compliance4 records

APR Applied Pharma Research financial estimates

Financial estimate

Revenue estimate

Valuation estimate

APR Applied Pharma Research leadership team

Management profile

Number of profiles

Profiles1 record

APR Applied Pharma Research subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

APR Applied Pharma Research funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

APR Applied Pharma Research M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about APR Applied Pharma Research

What does APR Applied Pharma Research do?

APR Applied Pharma Research is a Swiss pharmaceutical company that identifies, develops, and commercializes patent-protected, science-driven products in niche and rare therapeutic areas. It markets branded prescription healthcare products (PKU GOLIKE family, Nexodyn, Diclofenac IR, Setofilm) and consumer healthcare OTC products (Halykoo, SwitzAGE), and additionally provides contract R&D and formulation development services on a fee-for-service basis.

Is APR Applied Pharma Research a public or private company?

APR Applied Pharma Research is a private company. It is classified as corporate owned and is currently operating.

When was APR Applied Pharma Research founded?

APR Applied Pharma Research was founded in 1990. It employs 11 to 50 people.

Where is APR Applied Pharma Research based?

APR Applied Pharma Research is headquartered in Balerna, Switzerland, in the Europe region.

How does APR Applied Pharma Research make money?

Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are contract R&D Services.

Who are APR Applied Pharma Research's main competitors?

Direct peers on record are BioMarin Pharmaceutical, ConvaTec, Recordati Rare Diseases, Nestlé Health Science, Nutricia (Danone), Sobi (Swedish Orphan Biovitrum) and Ajinomoto Health & Nutrition (formerly Cambrooke Therapeutics). Broad incumbents are Almirall, Chiesi Farmaceutici and Smith & Nephew.

Does APR Applied Pharma Research have an API?

No public API is recorded for APR Applied Pharma Research.

What industry is APR Applied Pharma Research in?

APR Applied Pharma Research's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireAPR Applied Pharma Research (una controllata di Relief Therapeutics) è tra i finalisti del Rare Disease International Film Festival 2022Relief Therapeutics' wholly-owned subsidiary APR Applied Pharma Research was nominated as a finalist at the UnoSguardoRaro Rare Disease International Film Festival 2022, with its short film 'Forward – Live your best life' winning two awards (Special Mention for Best Campaign and Best Direction) among over 200 participants. The film highlights the emotional journey of families affected by Phenylketonuria (PKU) and promotes their PKU GOLIKE® product, a phenylalanine-free amino acid food for medical purposes launched in Europe in 2019 and in the United States in October 2022. APR participated in festival events across Berlin, Rome, and Milan as part of its outreach activities.PR NewswireAPR Applied Pharma Research (eine Tochtergesellschaft von Relief Therapeutics) ist unter den Finalisten des Rare Disease International Film Festival 2022APR Applied Pharma Research, a wholly owned subsidiary of Swiss biopharmaceutical company Relief Therapeutics, was named a finalist at the Rare Disease International Film Festival 2022 (UnoSguardoRaro), winning two awards for its short film 'Forward – Live your best life': Best Campaign and Best Direction. The film, submitted under APR's PKU GOLIKE® 'Live your best life' campaign, highlights the experiences of families affected by Phenylketonuria and was selected from over 200 candidates by an international jury. PKU GOLIKE®, developed using Relief's proprietary Physiomimic™ technology platform, is a phenylalanine-free amino acid product for the dietary management of PKU, which has been available in the EU since 2019 and launched in the US in October 2022.PR NewswireAPR Applied Pharma Research (filiale de Relief Therapeutics) est finaliste de l'édition 2022 du Festival international du film sur les maladies raresRelief Therapeutics Holding SA announced that its wholly-owned subsidiary APR Applied Pharma Research was named a finalist at the 2022 UnoSguardoRaro International Film Festival on Rare Diseases, with its short film "Forward – Live your best life" winning two awards: a special jury mention for best campaign and the best direction award. The film, which depicts the emotional journey of families affected by Phenylketonuria (PKU), was inspired by the real-life story of APR's CEO Paolo Galfetti and his son Riccardo, born with the rare metabolic disorder. Relief also noted that PKU GOLIKE®, its flagship amino acid product for PKU management developed with its proprietary Physiomimic™ technology platform, was commercially launched in the United States in October 2022.PR NewswireAPR es finalista en el Festival Internacional de Cine sobre Enfermedades Raras de 2022Relief Therapeutics announced that its subsidiary APR Applied Pharma Research was nominated as a finalist at the 2022 International Rare Disease Film Festival (UnoSguardoRaro), winning two awards — a special mention for best campaign and best direction — for its short film "Forward – Live your best life." The film, inspired by the real-life experience of APR's CEO whose son was born with phenylketonuria (PKU), highlights the challenges families face managing the strict dietary requirements of the disease while promoting the company's PKU GOLIKE® product line. PKU GOLIKE® is a phenylalanine-free amino acid medical food developed using Relief's proprietary Physiomimic™ technology and launched in the EU in 2019 and in the United States in October 2022.PR NewswireAPR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film FestivalAPR Applied Pharma Research, a subsidiary of Swiss biopharmaceutical company Relief Therapeutics, was nominated as a finalist in the 2022 Rare Disease International Film Festival, winning Special Mention for Best Campaign and Best Direction for its short movie about phenylketonuria (PKU) patients and families. The film "Live your best life!" was inspired by the real-life experience of APR's CEO whose son was born with PKU, and highlights the challenges families face in managing the strict diet and protein substitutes required for the condition. APR's PKU GOLIKE® product line, developed using Relief's proprietary Physiomimic™ Technology, was commercially launched in the U.S. in October 2022.PR NewswireAPR Applied Pharma Research (a Subsidiary of Relief Therapeutics) is a Finalist in the 2022 Rare Disease International Film FestivalAPR Applied Pharma Research, a subsidiary of Relief Therapeutics, was nominated as a finalist and won two awards (Special Mention for Best Campaign and Best Direction) at the 2022 Rare Disease International Film Festival UnoSguardoRaro for its short movie highlighting the experiences of PKU (phenylketonuria) families. The company's PKU GOLIKE\u00ae product line, a prolonged-release amino acid food for special medical purposes, was commercially launched in the U.S. in October 2022 after being available in the E.U. since 2019. APR attended festival events across Berlin, Rome, and Milan as part of its participation.BioSpaceRelief Therapeutics Announces Promotion of Paolo Galfetti to Chief Operating OfficerRelief Therapeutics promoted Paolo Galfetti to Chief Operating Officer, effective October 14, 2022. He will continue as CEO of APR Applied Pharma Research and a board member. The promotion supports the U.S. launch of PKU GOLIKE and future development of ACER-001.PR NewswireRelief Therapeutics to Webcast Live at Life Sciences Investor Forum on December 16thRelief Therapeutics Holding SA announced that Chief Financial Officer Jack Weinstein will present a company overview live at the VirtualInvestorConferences.com event on December 16th, 2021, at 10:30 am EST. The live, interactive online event will allow investors to ask questions in real-time, with an archived webcast available afterward. Relief's pipeline includes RLF-100 (aviptadil) in late-stage U.S. clinical testing for COVID-19 respiratory deficiency, and the company recently acquired APR Applied Pharma Research SA and AdVita Lifescience GmbH to expand its marketed and development-stage programs.BioSpaceRelief and APR Applied Pharma Research Sign and Close Definitive Agreement for Relief to Acquire All Outstanding Shares of APRRelief Therapeutics Holding AG has closed its definitive agreement to acquire all outstanding shares of APR Applied Pharma Research S.A. for a total consideration of CHF 66.5 million in cash and stock, plus potential milestone payments. This acquisition integrates APR's commercial infrastructure and pipeline into Relief, transforming it into a fully integrated commercial-stage biopharmaceutical company with expanded capabilities in rare diseases.